All In Biotech

Drug Trial Radar · NCT07549321

A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients

A Phase 2/3 Study to Characterize and Evaluate the Efficacy, Safety, and Tolerability of hu14.18K322A Treatment Given in Combination With Chemotherapy in Participants With High-Risk Neuroblastoma

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 144 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

144

Planned (sponsor's estimate)

Start

Mar 30, 2026

Primary completion

Mar 2031

Study completion Mar 2031

Sponsor

Lead sponsor
Renaissance Pharma Ltd.Industry
Sponsor type
Industry
First posted
Apr 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 months, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Neuroblastoma is the most common type of solid cancer found outside the brain in young children. Generally, it affects children younger than 5 years old, with the average age when it is found being just 2 years. Most patients have 'high-risk' disease, with spread of the disease to different sites (metastases). This multinational study aims to find out how effective and safe the treatment of a monoclonal anti-GD2 antibody hu14.18K322A (daretabart) is when used together with chemotherapy to treat children and young people who have high-risk neuroblastoma.

Conditions

  • High-Risk Neuroblastoma

Interventions

  • hu1418K322A + Temozolomide + IrinotecanDrug

    21-day cycle for a maximum of 12 cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall response rate (ORR)Time frame: Assessed at end of treatment (up to 12 months)
  2. Metastatic complete response rate (mCRR)Time frame: Assessed at end of treatment (up to 12 months)

Locations

20 sites in 7 countries. Site status is shown where the registry gives one.

  • University of California San Francisco (UCSF)

    San Francisco, California · Recruiting

  • Children's Hospital Colorado Anschutz Medical

    Aurora, Colorado · Recruiting

  • The University of Chicago

    Chicago, Illinois · Recruiting

  • University of Minnesota Masonic Children's Hospital

    Minneapolis, Minnesota · Recruiting

  • The Children's Hospital at Montefiore

    The Bronx, New York · Recruiting

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • University of Texas Southwestern

    Dallas, Texas · Recruiting

  • The Hospital for Sick Children

    Toronto, Ontario, Canada · Recruiting

  • Rigshospitalet

    Copenhagen, Denmark · Recruiting

  • La Timone Children's Hospital

    Marseille, France · Recruiting

  • Institut Curie

    Paris, France · Recruiting

  • Gustave Roussy

    Villejuif, France · Recruiting

  • Charité - Universitätsmedizin Berlin

    Berlin, Germany · Recruiting

  • University Hospital Vall d'Hebron

    Barcelona, Spain · Recruiting

  • Hospital Sant Joan de Deu

    Barcelona, Spain · Recruiting

  • Hospital Infantil Universitario Niño Jesús

    Madrid, Spain · Recruiting

  • Royal Victoria Infirmary

    Newcastle upon Tyne, United Kingdom · Recruiting

  • Royal Marsden NHS Foundation Trust

    Sutton, United Kingdom · Recruiting

  • Southampton Children's Hospital

    Southampton, Hampshire, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.